Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT05681715

A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)

Conditions: Generalized Myasthenia Gravis

Sex: All
Ages: 18 Years – N/A
Phase: PHASE3
Enrollment: 30
Sponsor: UCB Biopharma SRL

Summary

The purpose of this study is to evaluate the ability of study participants with generalized Myasthenia Gravis (gMG) to successfully self-administer rozanolixizumab after training in the self-administration technique using the syringe driver and manual push methods.

Eligibility Criteria

Inclusion Criteria:Study participant must have a documented diagnosis of generalized Myasthenia Gravis (gMG)Study participant is willing to perform and capable of performing home self-administrationStudy participant is considered by the investigator for additional rozanolixizumab treatment with the posology proposed in this study.Body weight ≥35 kgStudy participants may be male or femaleExclusion Criteria:Study participant has a known hypersensitivity to any components of the study medication or other anti-neonatal Fc receptor (FcRn) medicationsStudy participant with a known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent tuberculosis infection (LTBI), or current or history of nontuberculous mycobacterial infection (NTMBI)Study participant has a clinically relevant active infection or a history of serious infection (resulting in hospitalization or requiring IV antibiotic treatment) within 6 weeks before the Baseline VisitThe study participant previously participated in any rozanolixizumab MG study and met any mandatory withdrawal or mandatory study drug discontinuation criteriaStudy participant has received a live vaccination within 4 weeks before starting treatment, or a Bacillus Calmette-Guérin (BCG) vaccine within 1 year before starting treatment; or intends to have a live vaccination during the course of the study or within 8 weeks following the last dose of rozanolixizumabStudy participant with severe (defined as Grade 3 on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale) weakness affecting oropharyngeal or respiratory muscles, or who has myasthenic crisis or impending crisis

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05681715). StuddyBuddy aggregates publicly available trial information.